Sai Parenteral's consolidated net profit surged 975% to ₹7.9 crore in Q1 FY2027, compared to ₹1.42 crore in the corresponding quarter of the previous year. According to the latest unaudited financial results approved by the Board on August 11, 2026, this represents one of the most significant profit growth rates in the company's recent financial performance. The standalone net profit also showed remarkable growth of 975% to ₹8.9 crore from ₹0.8 crore in Q1 FY2026, demonstrating the company's strong operational performance during the quarter.
The company's consolidated revenue reached ₹182.4 crore in Q1 FY2027, compared to ₹34.6 crore in the same quarter of the previous financial year. On a standalone basis, revenue from operations grew by 175% to ₹52.8 crore from ₹19.2 crore in Q1 FY2026. As reported in the latest financial statements, this substantial revenue growth demonstrates the company's strong operational performance during the quarter, with the strong top-line growth outpacing expense increases and leading to expanded profitability metrics.
The Board of Directors approved strategic acquisitions totaling ₹101.85 crore to boost capacity and R&D capabilities. The company will utilize ₹83.83 crore originally earmarked for upgrading Unit I and Unit II manufacturing facilities to acquire a 60% equity stake in Saicriti Pharma Private Limited. This acquisition involves a state-of-the-art critical care sterile injectable manufacturing facility at Gummadidala, Hyderabad, with a total estimated development cost of ₹215 crore and completion targeted for April 2027. Additionally, ₹18.02 crore allocated for establishing a new Research & Development Centre will be redirected to acquire a 60% stake in Prathyak Laboratories Private Limited, an established pharmaceutical R&D platform with a pipeline of 150 SKUs and 28 research scientists.
The company's operating profit margin (OPM) stood at 13.16% in the June 2026 quarter, compared to 14.23% in the corresponding quarter of the previous year. The consolidated EBITDA margin contracted slightly to 14.9% from 17.1% in the prior year period, primarily due to elevated air-freight costs in Australia arising from industry-wide shipping disruptions and the fact that the Noumed platform currently operates at distribution margins pending the commencement of in-house manufacturing at Adelaide. However, gross margins improved sequentially to 41.8% from 38.1% in Q4 FY2026, indicating that negotiated price revisions are beginning to offset raw material cost increases.
